Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
Giampaolo Bianchini(IRCCS Ospedale San Raffaele), Luca Gianni(IRCCS Ospedale San Raffaele)
Cited by 129
Related Papers
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study
|Annals of Oncology|2022|382
Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours
|British Journal of Cancer|2014|103